9/17/2020
1
Disclosures:
Brooks D. Cash, MD, FACGConsultant/Speakers’ Bureau: Salix, Allergan, Takeda, Ironwood, Alfasigma, Arena
DSMB: Vibrant
Brian E. Lacy, MD, PhD, FACG No conflicts of interest.
Current and Emerging Concepts in Irritable Bowel
Syndrome
Brooks D. Cash, M.D., FACP, FACG, FASGE, AGAFDan and Lillie Sterling Professor of Medicine
McGovern Medical SchoolChief, Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science CenterHouston, TX
1
2
American College of Gastroenterology
9/17/2020
2
• Consultant/Speakers’ Bureau: Salix, Allergan, Takeda, Ironwood, Alfasigma, Arena
• DSMB: Vibrant
Disclosures
Objectives
1.Discuss the pathophysiology and diagnostic criteria for IBS
2.Explore the data for lifestyle and over the counter therapies for IBS symptoms
3.Review the mechanisms of action, efficacy, and safety profiles of FDA approved IBS therapies
4.Examine emerging therapies for IBS
3
4
American College of Gastroenterology
9/17/2020
3
McGovern Medical School
Rome IV Criteria for IBS
Lacy BE, et al. Gastroenterology. 2016
Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
Associated with a change
in stool frequency
Associated with a change
in stool form
Related to defecation
Recurrent abdominal painat least 1 day/week (on average) in the last 3 months
associated with ≥ 2 of the following
McGovern Medical School
Multifactorial Pathophysiology of IBS
IBS Symptom Complex
Abnormal Motility
Visceral Hypersensitivity
Genetic Predisposition
Psychosocial Factors
Inflammation, Immune
Dysregulation
Microbiome
Malabsorption Issues
Diet
Chey WD, et al. JAMA. 2015;313:949‐958. Drossman DA. Gastroenterology. 2016;150:1262‐1279. Holtmann G, et al. Dig Dis. 2017:35:5‐13. Radovanovic‐Dinic B, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162:1‐9.
5
6
American College of Gastroenterology
9/17/2020
4
McGovern Medical School
Principles of IBS Management
• Exclude organic GI disease• Make a positive diagnosis
• Establish a rapport; educate and reassure
• Categorize IBS subtype based on prevalent stool form (BSFS)
• First line: lifestyle and dietary modifications and OTC therapies targeting abnormal stool form/most bothersome symptoms
• Escalate to FDA approved/validated therapies
• Non‐FDA/off‐label/psychological therapies
McGovern Medical School
All IBS Subtypes1
• CRP or fecal calprotectin
• IgA TtG ± quantitative IgA
• Stool diary/App
• Consider abdominal plain film to assess for fecal loading
If severe or medically refractory, refer to specialist for physiologic testing
Diagnostic Testing for Suspected IBS and No AlarmFeatures*
• CRP or fecal calprotectin
• IgA TtG ± quantitative IgA
• When colonoscopy performed,
obtain random biopsies
• Serum 7‐C4 or fecal bile acids where available
IBS‐D1,2IBS‐D1,2IBS‐D1,2 IBS‐M1IBS‐M1IBS‐M1 IBS‐C1IBS‐C1IBS‐C1
CBCAge‐appropriate CRC screening
1. Chey WD et al. JAMA. 2015;313(9):949‐958. 2. Pimentel M et al. PLoS ONE. 2015;10(5):e0126438.
C4, 7α‐hydroxy‐4‐cholesten‐3‐one; CRC, colorectal cancer screening; CRP, C‐reactive protein; Ttg, tissue transglutaninase
*Alarm Features include age ≥50 years old, blood in stools, nocturnal symptoms, unintentional weight loss, change in symptoms, recent antibiotic use, and family history of organic GI disease
7
8
American College of Gastroenterology
9/17/2020
5
McGovern Medical School
Lifestyle Modifications (all have some evidence of benefit)
• Dietary• Low FODMAP
• Gluten restriction
• Keto/Mediterranean
• Low fat
• Activity• Exercise
• Sleep hygiene
• Minimize/eliminate ETOH• Best evidence for IBS‐D, likely due to decrease in metabolic byproducts
McGovern Medical School
Dietary Considerations in IBS
• FODMAPS are an important trigger of meal‐related symptoms in IBS1
• Low FODMAP diet found to improve overall symptom scores compared with typical diet in IBS patients2
• Gluten‐free diet found to be beneficial in some patients with IBS‐D3,4
–Wheat contains fructans and other proteins that may also cause symptoms in IBS patients5
–Most patients who associate their symptoms with wheat will have wheat sensitivity, not celiac disease6
• Food antigens found to cause changes in the intestinal mucosa of IBS patients that are associated with patient responses to exclusion diets7
1. Shepherd SJ et al. Am J Gastroenterol. 2013;108:707‐717. 2. Halmos EP et al. Gastroenterology. 2014;146:67‐75.3. Biesiekierski JR et al. Gastroenterology. 2011;106:508‐514. 4. Vazquez‐Roque MI et al. Gastroenterology. 2013;144:903‐911.e3. 5. Chey WD, et al. JAMA. 2015;313(9):949‐958. 6. Leonard MM et al. JAMA. 2017;318(7):647‐656. 7. Fritscher‐Ravens A et al.Gastroenterology. 2014;147:1012‐1020.
9
10
American College of Gastroenterology
9/17/2020
6
McGovern Medical School
84 patients with IBS‐D randomized to LFD or mNICE x 4 weeks and completed study‐median age was 43 years (range 19‐68); 65 were women
Percent
Responders
52
41
0
20
40
60
80
LFD mNICE
Adequate Relief
27
13
0
20
40
60
80
LFD mNICE
FDA Composite Responder
>30% reduction in pain and decrease in BSFS >1 compared to baseline
P = 0.13
Low FODMAP versus mNICE Diet for IBS‐D: Adequate Relief & FDA Endpoint
P = 0.31
Eswaran SL et al. Am J Gastroenterol. 2016;111(12):1824‐1832.
Percent
Responders
n=45 n=45n=39 n=39
McGovern Medical School
IBS Pharmacologic Options by Symptom1,2
1. Brandt LJ, et al. Am J Gastroenterol. 2002;97(11 suppl):S7‐S26. 2. Drossman DA et al. Gastroenterology. 2002;123:2108‐2131.
Abdominalpain/
discomfort
Bloating/distension
Altered bowelfunction
Constipation Fiber* MOM/PEG solution* Lubiprostone Linaclotide Plecanatide Tegaserod Tenapanor Prucalopride*
Diarrhea Loperamide* Diphenoxylate‐
atropine* Cholestyramine* Alosetron Rifaximin Eluxadoline
Bloating
Rifaximin Lubiprostone Linaclotide Plecanatide Probiotics*
*Not currently FDA‐approved for IBS
Abdominal Pain/discomfort Antispasmodics* Antidepressants* Lubiprostone Linaclotide Plecanatide Alosetron Rifaximin Eluxadoline Tegaserod
11
12
American College of Gastroenterology
9/17/2020
7
McGovern Medical School
OTC Options
• Antidiarrheals: Imodium, clays/binders
• Anti‐spasmodics
• Peppermint oil
• Probiotics
McGovern Medical School
Conventional Nonspecific Agents for IBS‐D
14
Ford AC et al. Am J Gastroenterol. 2014;109(Suppl 1):S2‐S26.
There is insufficient evidence to recommend
loperamide for use in IBS
There is insufficient evidence to recommend
antispasmodicsavailable in US*
Clinical trials
Patients treated
23
2,154
Clinical trials
Patients treated
2
42
Recommendation
Strong
Quality of evidence
Very Low
Recommendation
Weak
Quality of evidence
Low
*Recommendation revised to reflect evidence for products available in US
Recommendations from an American College of Gastroenterology monograph
13
14
American College of Gastroenterology
9/17/2020
8
McGovern Medical School
Peppermint Oil
• Active ingredients: L‐menthol, rosmarinic acid, limonene1
• Primary effect: Ca+2 channel smooth muscle relaxation
• Possible mediation via TRPM8, k‐opioid agonist, antibacterial, anti‐inflammatory, carminative2
• Dose unclear; typically 90‐180 mg up to TID
• 7 RCT, 634 patients
• NNT = 4
• AEs similar to placebo: GERD, dyspepsia reported
Cash BD et al. Dig Dis Sci. 2016;61:560‐571. HenstromM et al. Gut. 2017;66(9):1725‐1727.
McGovern Medical School
Probiotics
• 53 RCT, 5545 patients; 50% trials at low risk for bias
• Significant heterogeneity• Evidence of publication bias
• Probiotics superior to placebo• NNT=7
• Combination probiotics: RR = 0.79 (0.68‐0.91)
• IBS dose/brand: unknown• Symptoms most likely to improve pain, bloating, flatulence
• Low rate of AEs
Ford AC et al. Am J Gastroenterol. 2018;113(Suppl 2):1‐18.
•.
15
16
American College of Gastroenterology
9/17/2020
9
McGovern Medical School
FDA Approved Therapies for IBS‐D
• Rifaximin
• Eluxadoline
• Alosetron
McGovern Medical School
Rifaximin for IBS‐DTARGET 1 & TARGET 2 Trials
• Poorly absorbed antibiotic; inhibits protein synthesis
• Dosing 550 mg TID x 2 weeks• 7 RCT; 2654 patients • NNT= 8• AEs similar to placebo• 2/3 responders need repeat treatment
• No value in re‐treating non‐responders
Pimentel M et al. N Engl J Med. 2011;364(1):22‐32.
Adequate Relief of IBS‐Related Bloating
TARGET 1 TARGET 2 Combined
40.8 40.6 40.7
31.2 32.2 31.7
0
20
40
60
80
Patients, %
P = .01
n=309 n=314 n=315 n=320 n=624 n=634
P = .03P < 0.001
Adequate Relief of Global IBS Symptoms
TARGET 1 TARGET 2 Combined
39.5 41 40.2
28.731.9 30.3
0
20
40
60
80
P = .005
n=309 n=314 n=315 n=320 n=624 n=634
P=.02 P < .001
Adequate Relief of Bloating
Rifaximin Placebo
17
18
American College of Gastroenterology
9/17/2020
10
McGovern Medical School
Urgency and bloating improved significantly with both repeat treatments
Abdominal pain and stool consistency improved significantly with first retreatment
Rifaximin for IBS‐DTARGET 3 Trial
33 36.9
2529.3
0
20
40
60
80
P = .04P = .02
n=328 n=308 n=295 n=283
Lembo A et al. Gastroenterology. 2016;151(6):1113‐1121.
Patients, %
First Repeat Treatment
Second Repeat Treatment
Rifaximin Placebo
Responder defined as • Responding to IBS‐related abdominal pain
and stool consistency for ≥2 of 4 weeksRecurrence defined as • Loss of response for ≥3 of 4 weeks
Data for last observation carried forward
Retreatment Efficacy
McGovern Medical School
Eluxadoline for IBS‐DIBS‐3001 & IBS‐3002 Trials
• Mixed opioid receptor modulator
• μ/κ‐opioid receptor agonist; δ‐opioid antagonist 1,2
• Dosing: 100 mg BID
• 3 RCT, 3235 patients
• NNT= 13
• AEs: Constipation, abdominal pain, SO spasm, pancreatitis
• Contraindicated if no GB or h/o pancreatitis, heavy ETOH users
Fujita W et al. Biochemical Pharmacology. 2014;92(3):448‐4565.; Wade PR et al. British Journal of Pharmacology. 2012;167(5):1111‐1125; ; Viberzi. Allergan; 2018. Accesses May 26, 2020. https://www.allergan.com/assets/pdf/viberzi_pi.; Lembo AJ et al. N Engl J Med. 2016;374(3):242‐253.
Placebo BID Eluxadoline 75 mg BID Eluxadoline 100 mg BI
Composite responder defined as
• 30% reduction in worst abdominal pain score AND improvement in stool consistency of <5 on the Bristol Stool Scale
• Daily improvement in BOTH symptoms on at least 50% of days in the trial
Composite Responder Rates
19
20
American College of Gastroenterology
9/17/2020
11
McGovern Medical School
Eluxadoline in Patients Who Failed LoperamideRELIEF Trial
Brenner DM et al. Am J Gastroenterol 2019:114(9):1502‐1511.
22.7%27.9%
43.6%
10.3%
16.7%
31.0%
0%
10%
20%
30%
40%
50%
60%
Primary Composite Secondary: StoolConsistency
Secondary: WorstAbdominal Pain
Eluxadoline 100 mg BID (n=174) Placebo BID (n=172)
% R
esp
on
der
s
Primary Composite = Patient met composite response criteria on ≥50% of days, defined as ≥40% improvement in WAP c/w BL and BSS <5 OR absence of a BM if accompanied by ≥40% improvement in WAP.Secondary Stool Consistency defined as BSS <5 on ≥50% of days. Secondary WAP defined as ≥40% improvement in WAP compared to BL, on ≥50% of days.
• Phase IV multicenter DBRCT
• Subjects: Patients subjectively reporting loperamide use in prior 12 months failing to provide adequate control of IBS‐D symptoms
• AEs: Rates comparable in both groups; no SAEs
P < .05
P < .01
P < .05
McGovern Medical School
Alosetron for IBS‐D
• Partially selective 5‐HT3 antagonist
• 8 RCT, 4341 patients (predominantly women)
• NNT=7.5
• AEs: constipation, colon ischemia: 1/1000 patient‐yrs
• 0.5 mg BID starting dose; may increase to 1 mg BID if well tolerated
• Current indication: Female patients with severe IBS‐D not responding adequately to conventional therapy1
US National Library of Medicine Daily Med. Alosetron hydrochloride tablet. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6c2fbb‐a76a‐497e‐8cf2‐a6dca8945a9d. Accessed May 26, 2020.
Ford AC et al. Am J Gastroenterol. 2014;109(Suppl 1):S2‐S26.
21
22
American College of Gastroenterology
9/17/2020
12
McGovern Medical School
AntidepressantsVariable Recs and Strength of Evidence
•18 RCT, 1127 patients •Antidepressants in general: NNT= 4; pain mostly
•TCAs: 12 RCT, 787 patients; NNT= 4; Strong rec, high evidence
•SSRIs: 7 RCT, 356 patients; NNT= 5; Weak rec, low evidence
•SNRIs not yet studied in large RCTs2
•AEs more common with antidepressants; NNH= 8.5
1. Ford AC et al. Am J Gastroenterol. 2014;109(9):1350‐1365. 2. Grover M, Drossman DA. Gastroenterol Clin N Am. 2011;40(1):183‐206. 3. Chey WD et al. Gut Liver. 2011;5(3):253‐266. 4.Gorard DA et al. Aliment Pharmacol Ther. 1994;8(2):159‐166.
Antidepressant action
Visceral analgesia
Changes in motility
Smooth muscle relaxation
McGovern Medical School
General Approach to Prescribing Antidepressants in IBS
• Consider specific symptoms1,2
– TCAs in IBS‐D, SSRIs in IBS‐C
– SSRI/SNRI for anxiety
• Consider side effect profiles1,2
– SSRIs may be better tolerated than TCAs
• Start with low dose and titrate slowly by response; allow 4‐8 weeks for maximal response1‐3
• Continue at minimum effective dose for 6‐12 months1,2
– Long‐term therapy may be warranted for some patients
– Gradual taper to prevent withdrawal symptoms
1. Sobin WH et al. Am J Gastroenterol. 2017;112 (5):693‐702. 2. Grover M, Drossman DA. Gastroenterol Clin N Am. 2011;40(1):183‐206. 3. Dekel R et al. Expert Opin Invest Drugs. 2013;22(3) :329‐339.
23
24
American College of Gastroenterology
9/17/2020
13
McGovern Medical School
RCTs NResponse*
Fiber Placebo
RR of Unimproved Symptoms(95% CI)
NNT(95%CI)
Overall 12 591 48% 43% 0.87 (0.76‐1.0) 11 (5‐100)
Ispaghula 6 321 48% 36% 0.78 (0.63‐0.96) 6 (3‐50)
Bran 5 221 46% 46% 1.02 (0.82‐1.27)
Bulking Agents for IBS‐C: Systematic Review and Meta‐analysis: Strong rec, weak evidence
*Improved or resolved symptoms.
• Insoluble fiber was not more effective and sometimes worsened symptoms
• Soluble fiber improved global symptoms
• 4 out of 5 bran studies of poor quality
CI = confidence interval; NNT = number needed to treat; RCTs = randomized, controlled trials; RR = relative risk
Ford, Quigley, Lacy et al, Am J Gastroenterol 2014
McGovern Medical School
FDA Approved Therapies for IBS‐C
• Linaclotide
• Plecanatide
• Lubiprostone
• Tegaserod
• Tenapanor
25
26
American College of Gastroenterology
9/17/2020
14
McGovern Medical School
Linaclotide for IBS‐C
• 14 aa peptide structurally similar to quanylin/uroguanylin; binds to guanylate‐cyclase C receptors to promote ion and fluid secretion into gut and ENS modulation
• 4 RCT, 2867 patients
• IBS‐C dose:290 mcg daily
• NNT=6
• AEs: diarrhea*P<0.0001 for all analyses of linaclotide vs placebo groups, using Cochran‐Mantel‐Haenszel test
% Responders
Placebo
(n=403)Linaclotide
290 μg (n=401)
FDA Primary Endpoint: ≥30% reduction worst abdominal pain and increase ≥1 CSBM, both for ≥6/12 weeks
Chey WD, et al. Am J Gastroenterol. 2012; epub September 18.
McGovern Medical School
Linaclotide for IBS‐C
CSB
M M
ean
Chan
ge from
Baselin
e +/‐SEM
3
2
1
0
Weeks
BL 1 2 3 4 5 6 7 8 9 10 11 12
Treatment Period*
Treatment PeriodPlaceboLinaclotide 290 µg
12 13 14 15 16
RW Period†
RW Treatment SequencePlacebo/linaclotide 290 µgLinaclotide 290 µg/linaclotide 290 µgLinaclotide 290 µg/placebo
z
Weeks
N=800
*P < 0.0001 for linaclotide patients vs placebo patients (ANCOVA).†P < 0.001 for linaclotide/linaclotide patients vs linaclotide/placebo patients (ANCOVA).
ANCOVA = analysis of covariance; RW = randomized withdrawal
Rao S, et al. Am J Gastroenterol 2012;107(11):1714-1724.
27
28
American College of Gastroenterology
9/17/2020
15
McGovern Medical School
Linaclotide: Abdominal Pain Over 26 Weeks
Chey WD, et al. Am J Gastroenterol. 2012;107:1702-1712.
ITT population, observed cases, LS‐mean presented: P‐values based on ANCOVA at each week. Bars represent 95% CI.
P=0.0007 for week 1P<0.0001 for weeks 2-26
Chan
ge in
Worst
Abdominal Pain, %
‐60
‐50
‐40
‐30
‐20
‐10
0
Trial Week
BL 2 4 6 8 10 12 14 16 18 20 22 24 26
Linaclotide 290 µg Placebo
N=804ITT, intention to treat; LS, least squares.
McGovern Medical School
Plecanatide for IBS‐C
• 16 aa peptide structurally similar to uroguanylin
• 8x greater binding affinity at GC‐C receptors at pH <7
• 3 RCT, all at low risk for bias, n=2612
• IBS‐C dose: 3mg daily
• NNT=10
• AEs: diarrhea17.8 30.2 29.5
* *
Overall Responder Rates (%)
Plecanatide 3 mg
(n=351)
Plecanatide 6 mg
(n=349)
Placebo (n=354)
*
*
14.2 21.5 24.0
Plecanatide 3 mg
(n=377)
Plecanatid6 mg
(n=379)
Placebo (n=379)
Overall Responder Rates (%)
Study ‐05Study ‐04
*P<0.001 vs placebo..Brenner D, et al. Am J Gastroenterol 2018; In press.
29
30
American College of Gastroenterology
9/17/2020
16
McGovern Medical School
Lubiprostone for IBS‐C
• Type 2 chloride channel activator; increases balanced ion and water secretion into gut
• 3 RCT, 1366 patients
• IBS‐C dose: 8 mcg BID only approved in women
• NNT=12.5• AEs: diarrhea and nausea
Drossman DA et al. Aliment Pharmacol Ther. 2009;29:329‐341.
17.9
10.1
0
25
50
Lubiprostone 8 µg BID Placebo
Overall Responders (%)
N=780 N=387
• Monthly responder: At least moderate relief for 4/4 weeks or significant relief for
2/4 weeks• Overall responder: Monthly responder for
at least 2 of 3 months
McGovern Medical School
Tegaserod for IBS‐C
Study B301 (n=325)
Study B358 (n=1181)
Study B307 (n=336)
Study B351 (n=359)
(N=2201)
Pooled, post hoc analysispatients with low CV risk
50
40
30
20
10
% Patients
Tegaserod(n=1122)
Placebo(n=1079)
OR 1.41 (1.19–1.68)
P<0.001
44
35
*Defined as patients who do not have a history of ischemic cardiovascular disease and who have no more than one cardiovascular disease risk factor.
• Mixed 5-HT (serotonin) agonist (prokinetic)• Approved for women < 65 yo with ≤ 1 CV risk factor• Dose: 6 mg PO BID• AEs: Diarrhea, abdominal pain, headache, nausea
Considerable or complete relief at least 50% of last 4 weeks in 12‐week studyor at least somewhat relieved 100% of the last 4 weeks.
31
32
American College of Gastroenterology
9/17/2020
17
McGovern Medical School
No demonstrable risk of MACE events with tegaserod
Favors Tegaserod Favors Comparator
0.93 0.72–1.21
0.95 0.73–1.23
0.89 0.45–1.75
0.90 0.46–1.77
Hazard Ratio 95% Confidence Interval
Non‐adjusted†
Non‐adjusted†
Adjusted‡
Adjusted‡
CV Events*
Stroke Events
Risk of Event
Risk of CV and stroke events with tegaserod vs comparators
0.1 1.0 10.0
*CV events include acute coronary syndrome, MI, coronary revascularization. †Unadjusted by Cox proportional hazards regression. ‡Adjusted for age, sex, region, calendar year, and baseline history of hypertension, treated hypertension, hyperlipidemia, statins, diabetes, treated diabetes, obesity, smoking, stroke, fibrates, angina, acute coronary syndrome, history of MI, and acute MI by Cox proportional regression.
Loughlin J, et al. J Cardiovasc Pharmacol Ther. 2010;15(2):151‐157.
McGovern Medical School
Tenapanor
• NHE3 Inhibitor: traps water and phosphate in GI lumen; pain modulation via TRPV‐1
• 50 mg BID resulted in significantly higher CSBM responder rate than placebo• Primary endpoint: Increase ≥1 CSBM/week from baseline for ≥6/12 treatment weeks
• FDA approved for IBS‐C 9/2019
• Most frequent AEs: diarrhea, headache, nausea, abdominal pain
Primary Endpoint
33.7
48.3
23.6
60.765.5
50
0
20
40
60
80
Placebo (n=308) Tenapanor 50 mg BID
Pa
tien
ts, %
P<0.001
≥1 CSBM increase ≥30% abdominal pain reduction
≥30% abdominal pain reduction and ≥1 CSBM increase in the same week
P<0.026
P<0.001
Secondary Endpoints
Chey WD et al. Am J Gastroenterol 2017; 112:763–774
33
34
American College of Gastroenterology
9/17/2020
18
McGovern Medical School
Emerging and Alternative IBS Therapies
• Bile acid sequestrants ‐ small, uncontrolled trials suggest benefit in IBS‐D
• Ramosetron – selective 5HT3 antagonist (IBS‐D)
• Tachykinin antagonists
• Peripheral cannabinoids – olorinab
• Mast cell stabilizers
• Glutamine
• TRPV agents
• Human milk oligosaccharrides
• FMT
Peters SL et al. Aliment Pharmacol Ther. 2016;44(5):447‐459.Holvoet T et al. 2018 Digestive Disease Week Annual Scientific Meeting. Abstract 617.Lackner JM et al. 2018 Digestive Disease Week Annual Scientific Meeting. Abstract 455.Camilleri M. Gut Liver. 2015;9(3):332‐339.
McGovern Medical School
Camilleri M. Gut Liver. 2015;9(3):332‐339.
Bile Acid Sequestrants
• BAM: prevalence estimates 1%; 25‐50% in IBS‐D
• Excess bile acids in colon • increase visceral sensation and fluid secretion via intracellular cAMP, mucosal permeability and/or Cl‐
secretion
• Uncontrolled trials of bile acid sequestrants suggest benefit in IBS; 4‐16 gm/day
• Availability of 7C4 serum test may identify likely responders; needs more study
35
36
American College of Gastroenterology
9/17/2020
19
McGovern Medical School
• High 5‐HT3 binding affinity: potent and prolonged receptor blockade and antiemetic effects compared with older 5‐HT3 antagonists
• Approved in Asia
• Meta‐analysis of 4 IBS RCTs; 1623 patients (ramosetron vs placebo)• Overall IBS relief OR 1.70 (95% CI: 1.48 to 1.95)
• Relief of abdominal pain/discomfort OR 1.41 (95% CI: 1.24 to 1.59)
• Improvement in diarrhea OR 1.71 (95% CI: 1.40 to 2.08)
• Higher rates of constipation; no colon ischemia
Ramosetron
Qi Q et al. BMC Gastroenterology 2018;18(1):5.
McGovern Medical School
Mast cell stabilizers
• Ketotifen• Up to 6 mg BID increased discomfort threshold with visceral hypersensitivity, improved abdominal pain bloating, flatulence, diarrhea, incomplete evacuation, HRQOL (n=15)1
• No effect on release of tryptase and histamine from rectal biopsies demonstrated, mechanisms other than mast cell stabilization H1 receptor antagonism may be involved1
• Cromolyn(disodium cromoglycate) • Significantly decreased abdominal pain behaviors induced by colorectal distension in animal model independent of mast cell mediator release2
1. Klooker TK et al. Gut 59(9):1213‐1221. 2. Carroll SY et al. PLoS One. 2013;8(12):e84718.doi: 10.1371.
37
38
American College of Gastroenterology
9/17/2020
20
McGovern Medical School
TRPV Agents
• Up‐regulation/sensitization of receptors on peripheral nerve terminals of nociceptors is an important mechanism of visceral hypersensitivity
• Transient reporter potential channel V1 (TRPV1), is involved in this process
• Responsive to capsaicin, heat, acidosis, and endovanilloids)
• Ebastine: H1RA • Small placebo‐controlled study (n=55) showed 20 mg/d reduced visceral hypersensitivity and abdominal pain in patients with IBS
Wouters MM et al. Gastroenterology. 2016;150(4):875‐887.
McGovern Medical School
Human Milk Oligosaccharides (HMOs)
HMOs in infant health1
• Primary determinant of gut microbiota
• Involved in maturation of gut barrier and gut immune function; bind pathogens
HMOs in IBS2,3
• Specifically increase bifidobacteria abundance
• Increase concentration of metabolites essential for gut barrier functioning and immune modulation
1. Bode L. Glycobiology 2012:22(9):1147‐1162. 2. Iribarren C et al. 2019 Digestive Disease Week Annual Scientific Meeting. Abstract 1145. 3. Vigsnæs LK et al. 2017 11th Vahouny Fiber Symposium. Presentation 2.
39
40
American College of Gastroenterology
9/17/2020
21
McGovern Medical School
HMOs: Change in Total % of Stool Consistency (BSFS)
Significantly reduced total % of abnormal stools (diarrhea + constipation) compared to baseline at P < .001
Simrén M et al. 2019 American College of Gastroenterology Annual Scientific Meeting. Abstract 43.
McGovern Medical School
Fecal Microbiota Transplant for IBSCharacteristics of randomized controlled trials of FMT versus placebo in IBSStudy, Year Study
population
Setting Study
Site
Sample
Size
IBS Criteria IBS Subtypes Primary outcome
Johnsen, 20171 Single
center
Primary care Norway 90 Rome III IBS‐D 53%
IBS‐C 47%
Decrease in IBS‐SSS > 75 points at
3 months
Holvoet 20182 Single
center
Tertiary care Belgium 64 Rome III Predominant
bloating and
non‐C
Yes to question of improvement in
overall symptoms and abdominal
bloating at 12 weeks
Aroniadis, 20183 Multi‐
center
Primary, secondary,
and tertiary care
USA 48 Rome III IBS‐D Decrease in IBS‐SSS ≥ 50 points at
12 weeks
Halkjaer, 20183,4 Two
centers
Tertiary care Denmark 52 Rome III All subtypes
33.3% IBS‐C
29.4% IBS‐D
37.3% IBS‐M
Decrease in IBS‐SSS ≥ 50 points at
3 months
FMT, fecal microbiota transplantation; IBS‐QOL, Irritable Bowel Syndrome‐Quality of Life Measure; HADS; IBS‐Hospital Anxiety and Depression Scale
1. Johnsen PH et al. Lancet Gastroenterol Hepatol.2018;3(1):17‐24. 2. Holvoet T et al. Gastroenterology. 2018;154:S130. 3. Aroniadis OC et al. 2018 American College of Gastroenterology Annual Scientific Meeting. Abstract 742. 4. Halkjaer SI et al. Gut. 2018;67(12):2107‐2115.
41
42
American College of Gastroenterology
9/17/2020
22
McGovern Medical School
Vibrating Capsule
Orally administrated vibrating capsule stimulates bowel motility by mechanically inducing vibrations in the large intestine
VIBRATING CAPSULE
PATIENT REPORTING APP Patients report bowel activity:• Allowing the physician to adjust the
treatment • Longitudinal, personalized data
collection for further development of treatment plans
ACTIVATING BASE UNIT The base unit activates the capsule prior to use. After placing a vibrating capsule into the designated groove , an activation signal is transmitted by the base unit to the capsule
McGovern Medical School
Vibrating Capsule Proof of Concept Trial• 24 patients with CIC (Rome III) randomized to vibrating vs sham capsule (2/week x 8 weeks)
• Endpoints: • Primary: Vibrating capsule vs sham colonic geometric center at 48 hours and t1/2 of ascending colon emptying
• Secondary: colonic geometric center at 8 and 24 hours and slope of progression of colonic geometric center over the 48 hours of the transit study
• Phase III trials ongoing for CIC with modified stimulation regimen
Nelson AD, et al. Neurogastroenterol Motil 2017; Jul;29(7). doi: 10.1111/nmo.13034. Epub 2017 Feb 8.
43
44
American College of Gastroenterology
9/17/2020
23
McGovern Medical School
Management of IBS: Take Home Points
• Make a positive diagnosis with judicious diagnostic testing
• Diet, lifestyle modifications, OTC (loperamide, fiber) therapies first line
• Best clinical trial evidence• IBS‐D: Rifaximin, Eluxadoline, Alosetron
• IBS‐C: Linaclotide, Plecanatide, Lubiprostone, Tegaserod, Tenapanor
• Adjunctive therapies (use at any point)• Peppermint oil (for all subtypes); TCAs, SNRIs (for IBS‐D/M with pain)‐allow 4 weeks minimum;
antispasmodics; CBT; Diet; Probiotics; Bile acid sequestrants
• Rich pipeline targeting specific etiologies/symptoms• Serotonergics, HMOs, tachykinin antagonists, mast cell stabilizers, FMT, glutamine,
TRP agonists, cannabanoids
McGovern Medical School
Thank [email protected]
713‐500‐6672
45
46
American College of Gastroenterology
9/17/2020
24
Questions?
Brooks D. Cash, MD, FACG
Brian E. Lacy, MD, PhD, FACG
47
48
American College of Gastroenterology